Interim Report for the period April – June 2021

FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...

Notice of Annual General Meeting in BioArctic AB (publ)

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...

BioArctic publishes the Annual Report for 2020

Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published. 

Proud partner of: